The UK BioIndustry Association (BIA) has launched a new advisory committee, which will focus on the issue of genomics.
committee
This new Genomics Advisory Committee will support the UK’s strategic objective for the initiation, scaling and building of globally leading genomics businesses. It will act as a platform for genomics businesses to share and discuss common concerns and issues, as well as provide expert advice on specific topics, such as the use of data and embedding genomic medicine in the NHS.
The committee has already garnered some success through its support of a panel on genomics that took place during the 36th annual JP Morgan Healthcare Conference at the beginning of the year.
“I am honoured to be the first Chair of this exciting new BIA Advisory Committee,” stated the chair of the Genomics Advisory Committee, Dr Adrian Ibrahim, of the Wellcome Sanger Institute. “Developments such as the 100,000 Genomes Project and research carried out by the Sanger Institute at the Wellcome Genome Campus in Hinxton Cambridge provide a solid foundation on which UK SMEs can build and grow. The BIA Genomics Advisory Committee will provide strength to the voice of this community.”
“I’m delighted to launch the new BIA Genomics Advisory Committee,” added BIA chief executive, Steve Bates OBE. “Genomic medicine is on the brink of transforming healthcare and the UK is at the forefront of this revolution. Convening this group will strengthen the voice of UK industry at an exciting and interesting time for genomics, working to ensure that the UK environment remains supportive and internationally competitive for genomic SMEs.”
Companies and organisations represented on the committee include Congenica, Eagle Genomics, Genomics plc, Global Gene Corp, LGC ltd, NewGene ltd, Oxford Nanopore Technologies ltd and the Wellcome Sanger Institute.